Key result
LAMP2 flow cytometry identifies 12% Danon disease prevalence in young females with advanced heart failure.
Why the study?
Danon disease is difficult to distinguish from other cardiomyopathies in females who regularly progress to advanced heart failure aged 20-40 years, making early identification critical.
What is the prevalence of Danon disease among young female patients with advanced heart failure, and can LAMP2 flow cytometry effectively identify it?
Cohort (n=60)
What is the prevalence of Danon disease among young female patients with advanced heart failure, and can LAMP2 flow cytometry effectively identify it?
Danon disease is an underdiagnosed cause of advanced heart failure in young women (12% prevalence in this cohort), and LAMP2 flow cytometry serves as an effective screening tool.
LAMP2 flow cytometry may aid Danon screening in young women with advanced HF; hypothesis-generating and requires prospective validation before practice change.
Aims Danon disease (DD) is a rare X-linked disorder caused by mutations in the lysosomal-associated membrane protein type 2 gene (LAMP2). DD is difficult to distinguish from other causes of dilated or hypertrophic cardiomyopathy (HCM) in female patients. As DD female patients regularly progress into advanced heart failure (AHF) aged 20–40 years, their early identification is critical to improve patient survival and facilitate genetic counselling. In this study, we evaluated the prevalence of DD among female patients with non-ischemic cardiomyopathy, who reached AHF and were younger than 40 years. Methods and results The study cohort comprised 60 female patients: 47 (78%) heart transplant recipients, 2 (3%) patients treated with ventricular assist device, and 11 (18%) patients undergoing pre-transplant assessment. Aetiology of the cardiomyopathy was known in 15 patients (including two DD patients). LAMP2 expression in peripheral white blood cells (WBC) was tested by flow cytometry (FC) in the remaining 45 female patients. Whole exome sequencing was used as an alternative independent testing method to FC. Five additional female DD patients (two with different novel LAMP2 mutations) were identified by FC. The total prevalence of DD in this cohort was 12%. HCM phenotype (57% vs. 9%, *P = 0.022) and delta waves identified by electrocardiography (43% vs. 0%, **P = 0.002) were significantly more frequent in DD female patients. Conclusions Danon disease is an underdiagnosed cause of AHF in young female patients. LAMP2 expression testing in peripheral WBCs by FC can be used as an effective screening/diagnostic tool to identify DD in this patient population.
No takes yet. Share an insight, caveat, or question.
Gurka et al. (2020) conducted a cohort in Advanced heart failure with non-ischemic cardiomyopathy (n=60). LAMP2 flow cytometry was evaluated on Prevalence of Danon disease. LAMP2 flow cytometry identified a 12% prevalence of Danon disease among young females with advanced heart failure, who more frequently exhibited an HCM phenotype (57% vs. 9%, P=0.022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: